Such replacement in leukemia cells would result in the rapid development of resistance, but we were surprised to discover that immunoproteasome was still predominant in MLL-86 PDX cells after a 4-week treatment with M3258 (Fig. 2c). Here, KMT2A is linked to leukemia.